Esophageal Cancer - Pipeline Review, H1 2015

Description: Esophageal Cancer - Pipeline Review, H1 2015

Summary

This, ‘Esophageal Cancer - Pipeline Review, H1 2015’, provides an overview of the Esophageal Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Esophageal Cancer Overview
Therapeutics Development
Pipeline Products for Esophageal Cancer - Overview
Pipeline Products for Esophageal Cancer - Comparative Analysis
Esophageal Cancer - Therapeutics under Development by Companies
Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes
Esophageal Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Esophageal Cancer - Products under Development by Companies
Esophageal Cancer - Products under Investigation by Universities/Institutes
Esophageal Cancer - Companies Involved in Therapeutics Development
Advantagene, Inc.
Advaxis, Inc.
Amgen Inc.
ArQule, Inc.
Aslan Pharmaceuticals Pte. Ltd.
AstraZeneca PLC
AVEO Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Cellectar Biosciences, Inc.
Cerulean Pharma, Inc.
Daichi Sankyo Company, Limited
Genmab A/S
GlaxoSmithKline plc
Glycotope GmbH
Hutchison MediPharma Limited
ImmunoFrontier, Inc.
ImmunoGen, Inc.
Immunomedics, Inc.
Karyopharm Therapeutics, Inc.
Mebiopharm Co., Ltd.
Meiji Seika Pharma Co., Ltd.
Merrimack Pharmaceuticals, Inc.
Novartis AG
Omeros Corporation
Omnitura Therapeutics Inc.
Oncolys BioPharma Inc.
Ono Pharmaceutical Co., Ltd.
Patrys Limited
Pfizer Inc.
Precision Biologics, Inc.
Proteo, Inc.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Supratek Pharma Inc.
Synta Pharmaceuticals Corp.
Takara Bio Inc.
Transgene Biotek Limited
Zhejiang BetaPharma Co., Ltd.
Esophageal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles
1-BB1 - Drug Profile
ADXS-HER2 - Drug Profile
afatinib - Drug Profile
alpelisib - Drug Profile
AMG-337 - Drug Profile
binimetinib - Drug Profile
BMS-833923 - Drug Profile
BPX-601 - Drug Profile
Cell Therapy 1 for Oncology - Drug Profile
Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile
cetuximab biobetter - Drug Profile
CRLX-101 - Drug Profile
dacomitinib - Drug Profile
DKN-01 - Drug Profile
doxorubicin - Drug Profile
Elafin - Drug Profile
ficoluzumab - Drug Profile
ganetespib - Drug Profile
gefitinib - Drug Profile
Gene Therapy for Esophageal Cancer - Drug Profile
Gene Therapy to Activate p53 for Oncology - Drug Profile
GSK-2256098 - Drug Profile
HMPL-309 - Drug Profile
HMPL-813 - Drug Profile
HuMax-TF-ADC - Drug Profile
I131-CLR1404 - Drug Profile
icotinib hydrochloride - Drug Profile
IMF-001 - Drug Profile
IMGN-289 - Drug Profile
IMMU-132 - Drug Profile
LJM-716 - Drug Profile
MBP-426 - Drug Profile
MM-111 - Drug Profile
MMD-37K - Drug Profile
MVX-ONCO-1 - Drug Profile
NEO-201 - Drug Profile
nimotuzumab - Drug Profile
nivolumab (recombinant) - Drug Profile
OBP-301 - Drug Profile
OMN-54 - Drug Profile
paclitaxel albumin bound - Drug Profile
panitumumab - Drug Profile
PAT-LM1 - Drug Profile
patritumab - Drug Profile
rAAV-VICN003 - Drug Profile
rhLT28-171 - Drug Profile
selinexor - Drug Profile
Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Drug Profile
Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile
Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile
talaporfin sodium - Drug Profile
TBI-1201 - Drug Profile
TBL-0805E - Drug Profile
List of Tables
Number of Products under Development for Esophageal Cancer, H1 2015
Number of Products under Development for Esophageal Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015
Esophageal Cancer - Pipeline by Advantagene, Inc., H1 2015
Esophageal Cancer - Pipeline by Advaxis, Inc., H1 2015
Esophageal Cancer - Pipeline by Amgen Inc., H1 2015
Esophageal Cancer - Pipeline by ArQule, Inc., H1 2015
Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015
Esophageal Cancer - Pipeline by AstraZeneca PLC, H1 2015
Esophageal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Esophageal Cancer - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015
Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Esophageal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015
Esophageal Cancer - Pipeline by Celgene Corporation, H1 2015
Esophageal Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2015
Esophageal Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015
Esophageal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Esophageal Cancer - Pipeline by Genmab A/S, H1 2015
Esophageal Cancer - Pipeline by GlaxoSmithKline plc, H1 2015
Esophageal Cancer - Pipeline by Glycotope GmbH, H1 2015
Esophageal Cancer - Pipeline by Hutchison MediPharma Limited, H1 2015
Esophageal Cancer - Pipeline by ImmunoFrontier, Inc., H1 2015
Esophageal Cancer - Pipeline by ImmunoGen, Inc., H1 2015
Esophageal Cancer - Pipeline by Immunomedics, Inc., H1 2015
Esophageal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Esophageal Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2015
Esophageal Cancer - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015
Esophageal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015
Esophageal Cancer - Pipeline by Novartis AG, H1 2015
Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2015
Esophageal Cancer - Pipeline by Oncolytics BioPharma Inc., H1 2015
Esophageal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015
Esophageal Cancer - Pipeline by Patrys Limited, H1 2015
Esophageal Cancer - Pipeline by Pfizer Inc., H1 2015
Esophageal Cancer - Pipeline by Precision Biologics, Inc., H1 2015
Esophageal Cancer - Pipeline by Proteo, Inc., H1 2015
Esophageal Cancer - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2015
Esophageal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015
Esophageal Cancer - Pipeline by Takara Bio Inc., H1 2015
Esophageal Cancer - Pipeline by Transgene Biotek Limited, H1 2015
Esophageal Cancer - Pipeline by Zhejiang BetaPharma Co., Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Esophageal Cancer Therapeutics - Recent Pipeline Updates, H1 2015
Esophageal Cancer - Dormant Projects, H1 2015
Esophageal Cancer - Dormant Projects (Contd..1), H1 2015
Esophageal Cancer - Dormant Projects (Contd..2), H1 2015
Esophageal Cancer - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Esophageal Cancer, H1 2015
Number of Products under Development for Esophageal Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3112059/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Esophageal Cancer - Pipeline Review, H1 2015
Web Address: http://www.researchandmarkets.com/reports/3112059/
Office Code: SCD23G9J

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format Type</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>✔️</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>✔️</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>✔️</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Field</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title:</td>
<td>Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐</td>
</tr>
<tr>
<td>First Name:</td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World